Visiongainhas published a new report Point of Care Diagnostic Market Forecast 2020- 2030: Forecasts by Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Hematology Testing, Drugs-of-abuse Testing, Faecal Occult Testing, and Other POC Products) By Mode (Prescription-based, and OTC), By End User (Clinics, Hospitals, Home Care Setting, and Other End Users), and By Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) Including Forecasts by Major Developed Countries and Developing Countries, Profiles of Leading Companies in the Market &PLUS COVID-19 Recovery Scenarios
‘The global point of care diagnostics market was valued at $32,945 million in 2020 and is projected to reach $73,293 million in 2031’ says Visiongain’s lead analyst.
Download Exclusive Sample of Report @https://www.visiongain.com/report/poc-diagnostics-market-2021/#download_sampe_div
Point-of-care diagnostics is as an investigation undertaken at the time of the consultation with instantaneous availability of results to make speedy and informed decisions in relation to patient care. It allows physicians and medical staff to accurately achieve real-time, lab-quality diagnostic results within minutes rather than hours. Recent years have seen significant advances in point-of-care diagnostics test and devices.
Rise in prevalence of target condition has led to increase in adoption of PoC diagnostic in clinics, hospitals and even in homecare settings. Diabetes is a severe, long-term condition which can have a major impact on the lives and well-being of individuals, and families worldwide. According to International Diabetes Federation (IDF), in 2019, approximately 463 million adults were living with diabetes in the world which is further anticipated to rise to 700 million by 2045. China accounted for the largest number of people with diabetes followed by India which had the second highest diabetic population. The point of care diagnostics for glucose monitoring was the highest contributor to the global market and is anticipated to dominate the market during the forecast period 2021-2031.
Moreover, cardiovascular diseases (CVDs) are the number one cause of death globally, taking an estimated 17.9 million lives each year. Whereas, cancer is the second prominent cause of death globally, with an estimated 9.6 million deaths in a year. OTC or prescription based PoC tests assists in regular monitoring of blood glucose, to detect high troponin values for CVDs, and in early detection and screening of cancer biomarkers which further enables doctors to design an effective therapy and to figure out the necessity to admit the individual to the hospital. In 2020, the point of care diagnostics market for OTC was the highest contributor to the global market.
Other factors such as high prevalence of infectious diseases namely HIV, tuberculosis, malaria, Ebola, influenza, etc. in both developed and developing countries, is also expected to drive the adoption of PoC testing worldwide. Moreover, the ongoing pandemic of Covid-19 has put the world to standstill. According to WHO, there have been 107,423,526 confirmed cases of COVID-19, including 2,360,280 deaths as of February 2021. The US recorded more than 27.4 million Covid-19 cases followed by India and Brazil with 10.9 million & 9.7 million cases respectively as of February 2021. This has led to a high surge in demand for POC diagnostics in hospitals.
The Visiongain report analyst commented that “It is essential for the point of care diagnostic device manufacturers to focus on developing more PoC devices that can run multiple analyses on single device. These devices simultaneously measure multiple analyses on the same cartridge also known as multiplexing. Multiplex PoC tests has numerous advantages over widely adopted singleplex test such as greater output per sample, higher throughput and increased efficiency at lower costs. These advantages of multiplex devices over singleplex devices will help in gaining more resolute and detailed diagnostics and facilitate personalized medicine for patient suffering from various conditions.”
Get Detailed TOC @https://www.visiongain.com/report/poc-diagnostics-market-2021/#download_sampe_div
How the Point of care diagnostics Market report helps you
In summary, our 430+ page report provides you with the following knowledge:
• What is the current size of the overall global point of care diagnostics market? How much will this market be worth from 2021 to 2031?
• What are the main drivers and restraints that will shape the overall point of care diagnostics market over the next ten years?
• What are the main segments within the overall point of care diagnostics market? How much will each of these segments be worth for the period 2021 to 2031? How will the composition of the market change during that time, and why?
• What factors will affect that industry and market over the next ten years?
• Which are the leading companies and what are their activities, results, developments, and prospects?
• What are the main trends that will affect the world point of care diagnostics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities, and threats for the market?
• How will the global point of care diagnostics market evolve over the forecasted period, 2021 to 2031?
• Revenue forecasts to 2030 for 4 regional and 10 key national markets – the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Spain, Russia, China, Japan, Australia, South Korea, and India. The report also highlights growth potential in Latin America as well as Middle East & Africa.
• Prospects for established firms and those seeking to enter the market– including company profiles for over 15 of the major companies involved in the Point of care diagnostics market
Key players profiled in the report include: Abbott Laboratories, Roche, Quidel, AccuBiotech, Johnson & Johnson, Becton, Dickinson, and Company, Danaher Corporation, PTS Diagnostics, Trinity Biotech, Siemens Healthineers Group Chembio Diagnostic Systems, Instrumentation Laboratory, Nova Biomedical, Sekisui Diagnostics and Fluxergy.
In 2019, The North America point of care diagnostics market was the highest contributor to the global market. This is due to the growing prevalence of lifestyle diseases, and target conditions, supported by advance medical technology and increasing number of product approvals in the region. Whereas, Asia-Pacific point of care diagnostic market is anticipated to growth at the highest CAGR during the forecast period. This is attributed to high prevalence of infectious diseases, and large number of diabetic patients leading to rise in adoption of PoC tests in countries such as China and India. Also increase in government support indicates a favourable approval environment globally and which will encourage key manufacturers to focus and contribute to innovation thereby driving the market growth.
However, despite the high demand for PoC test and PoC diagnostic devices, manufacturers are facing several regulatory barriers due to multi-layered regulations set by the FDA and laboratory regulations under CLIA for the premarket approval of PoC testing kits which might pose a threat to the market growth.
To gain additional share in the point of care diagnostic market, key manufacturersare adopting several strategies and development such as new product launch/approval, acquisition, partnership, collaboration, expansion and technology development. For instance, In December 2020, Beckman Coulter a Danaher acquired company, launched the new Access SARS-CoV-2 Antigen assay capable of processing up to 200 samples per hour, enabling high throughput screening in just 30 minutes.
In November 2020, Becton, Dickinson and Company launched its rapid point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System. In October 2020, Siemens Healthineers launched rapid antigen test for the detection of SARS-CoV-2 in 15 minutes which helps in isolating covid-19 +ve patients sooner and avoid the spread. In May 2020, Chembio Diagnostic made an agreement with Thermo Fisher Scientific (US) to expand its commercial footprint in the US by strengthening the distribution channel for Chembio’s DPP COVID-19 system across the US.
Need industry data? Please contact us today.
Information found nowhere else
with our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the respiratory inhalers market and leading companies. You will find data, trends and predictions.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Find more research reports on the Pharma Diagnostics Industry, please click on the following links:
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
About Visiongain
Visiongain is one of the fastest growing and most innovative, independent, market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10-year forecast, are hundreds of pages long, with in depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which currently can influence one another, these markets include automotive, aviation, chemicals, cyber, defense, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.
Contact:
Sara Peerun
Commercial Director
Visiongain Inc.
Tel: + 44 207 549 9987
USA Tel: 00 1 718 682 4567
EU Tel: 00 353 1 695 0006
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.